KLP Kapitalforvaltning AS Has $16.01 Million Stake in Alnylam Pharmaceuticals, Inc. $ALNY

KLP Kapitalforvaltning AS raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 12.4% during the second quarter, according to its most recent filing with the SEC. The firm owned 49,100 shares of the biopharmaceutical company’s stock after purchasing an additional 5,400 shares during the period. KLP Kapitalforvaltning AS’s holdings in Alnylam Pharmaceuticals were worth $16,011,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Bayforest Capital Ltd lifted its stake in shares of Alnylam Pharmaceuticals by 14.6% in the 1st quarter. Bayforest Capital Ltd now owns 306 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 39 shares during the period. Fulton Bank N.A. lifted its stake in Alnylam Pharmaceuticals by 3.3% in the second quarter. Fulton Bank N.A. now owns 1,421 shares of the biopharmaceutical company’s stock valued at $463,000 after buying an additional 46 shares during the period. Northwestern Mutual Wealth Management Co. lifted its stake in Alnylam Pharmaceuticals by 10.3% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 525 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 49 shares during the period. Edmond DE Rothschild Holding S.A. lifted its stake in Alnylam Pharmaceuticals by 18.2% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 318 shares of the biopharmaceutical company’s stock valued at $86,000 after buying an additional 49 shares during the period. Finally, Lindbrook Capital LLC lifted its stake in Alnylam Pharmaceuticals by 9.2% in the first quarter. Lindbrook Capital LLC now owns 596 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 50 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on ALNY shares. UBS Group boosted their target price on shares of Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Oppenheimer upgraded shares of Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $490.00 price objective on the stock in a report on Monday, August 4th. Wells Fargo & Company upped their price target on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the stock an “equal weight” rating in a research note on Friday, August 1st. Morgan Stanley increased their price target on Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the stock an “equal weight” rating in a report on Monday. Finally, Barclays increased their price target on Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the stock an “overweight” rating in a report on Friday, August 1st. Twenty-four research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $448.04.

Insider Activity at Alnylam Pharmaceuticals

In related news, Director Colleen F. Reitan sold 18,000 shares of the firm’s stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $467.60, for a total transaction of $8,416,800.00. Following the transaction, the director directly owned 775 shares of the company’s stock, valued at $362,390. This trade represents a 95.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Yvonne Greenstreet sold 8,924 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $4,034,094.20. Following the transaction, the chief executive officer directly owned 65,409 shares in the company, valued at approximately $29,568,138.45. This represents a 12.01% decrease in their position. The disclosure for this sale can be found here. Insiders sold 98,144 shares of company stock valued at $44,160,261 over the last three months. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 1.9%

ALNY stock opened at $450.68 on Thursday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $484.21. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. The stock’s 50 day moving average is $448.91 and its 200-day moving average is $342.70. The firm has a market capitalization of $59.08 billion, a PE ratio of -182.46 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. During the same quarter last year, the company earned ($0.13) earnings per share. The company’s revenue for the quarter was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.